Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind,randomized,placebo-controlled clinical trials

Abstract

Three randomized, double-blind, placebo-controlled trials have shown that glatiramer acetate (GA) is effective in reducing relapse rate in patients with relapsing-remitting (RR) multiple sclerosis (MS). Using raw data pooled from 540 patients, we performed a meta-analysis of these three trials, to investigate whether the extent of G A efficacy varies according to disease-related variables at study entry. Three regression models were developed to assess the efficacy of G A on the annualized relapse rate (primary outcome measure), on the total number of on-trial relapses and on the time to first relapse. We also explored the efficacy of G A on accumulated disability and the potential role of baseline clinical variables as predicto rs of relapse-rate variables and treatment efficacy. The mean adjusted annualized relapse rate on study was 1.14 in the pooled placebo -treated subjects and 0.82 in the pooled GA group (P =0.004), indicating an average reductio n in annualized relapse rate of 28%. A bout a one third reductio n of the total number of on-trial relapses was also observed in patients receiving GA (P B-0.0001), who had a median time to the first relapse of 322 days versus a median time to the first relapse of 219 days seen in those receiving placebo (P =0.01). A beneficial effect on accumulated disability was also found (risk ratio of 0.6; 95%; C I =0.4-0.9; P =0.02). The drug assignment (P =0.004), baseline EDSS score (P =0.02) and number of relapses during the two years prior to study entry (P =0.002) were significant predicto rs of on-trial annualized relapse rate. No other demographic or clinical variable at baseline significantly influenced the treatment effect. This meta-analysis reaffirms the effectiveness of G A in reducing relapse rate and disability accumulatio n in RRMS, at a magnitude comparable to that of other available immunomodulating treatments. It also suggests that G A efficacy is not significantly influenced by the patients’ clinical characteristics at the time of treatment initiation.

Keywords

clinical trial glatiramer acetate interferon beta multiple sclerosis relapse rate

Get full access to this article

View all access options for this article.

References

Compston A , Matthews WB , Lassmann H , Ebers G , Wekerle H. McAlpine’s Multiple Sclerosis, third edition. New York: Churchill Livingstone , 1998.

The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group . Interferon beta- 1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 1995; 45: 1277-1285 .

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group . Randomised double-blind placebo-controlled study of inter-feron beta-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Ann Neurol 1996; 39: 285-294 .

Bornstein MB et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis . N Engl J Med 1987; 317: 408-414 .

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RP et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group . Neurology 1998; 50: 701-708 .

Comi G , Filippi M , Wolinsky JS. European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis . Ann Neurol 2001; 49: 290-297 .

Noronha A , Toscas A , Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis . J Neuroimmunol 1993; 46: 145-153 .

10.

Abu-Khabar KS , Armstrong JA , Ho M. Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell . J Leukoc Biol 1992; 52: 165-172 .

11.

Noronha AJM , Toscas A. TGF-beta activity in MS: effect of IFN-Beta . Neurology 1993; 43 (Suppl. 2): A355-A355 .

12.

Rudick RA , Ransohoff RM , Lee JC , Peppler R , Yu M , Methisen PM et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis . Neurology 1998; 50: 1294-1300 .

13.

Rudick RA , Ransohoff RM , Lee JC , Peppler R , Van der Brug Medendorp S , Lehmann P et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis . Ann Neurol 1996; 40: 618-627 .

14.

Cousens LP , Orange JS , Su HC , Biron CA. Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection . Proc Natl Acad Sci USA 1997; 94: 634-639 .

15.

Teitelbaum D , Aharoni R , Sela M , Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1 . Proc Natl Acad Sci USA 1991; 88: 9528-9532 .

16.

Teitelbaum D , Milo R , Arnon R , Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein . Proc Natl Acad Sci USA 1992; 89: 137-141 .

17.

Neuhaus O , Farina C , Wekerle H , Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis . Neurology 2001; 56: 702-708 .

18.

Arnon R. Suppression of demyelinating disease by synthetic copolymers. In Crescenzi GS ed. A multidisciplinaryapproach to myelin disease. Plenum: New York , 1988: 234-250.

19.

Miller A , Shapiro S , Gershtein R , Kinarty A , Rawashdeh H , Honigman S et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation . J Neuroimmunol 1998; 92: 113-121 .

20.

Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis . Neurology 2002; 58 (Suppl. 4): S3-S9 .

21.

Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

22.

Lublin FD , Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . Neurology 1996; 46: 907-911 .

23.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

24.

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group . Neurology 1995; 45: 1268-1276 .

25.

Bornstein MB , Miller A , Slagle S , Weitzman M , Drexler E , Keilson M et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis . Neurology 1991; 41: 533-539 .

26.

Molyneux PD , Filippi M , Barkhof F , Gasperini C , Yousry TA , Truyen L et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis . Ann Neurol 1998; 43: 332-339 .

27.

Kappos L , Moeri D , Radue EW , Schoetzau A , Schweikert K , Barkhof F et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group . Lancet 1999; 353: 964-969 .

28.

Weinshenker BG , Rice GP , Noseworthy JH , Carriere W , Baskerville J , Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome . Brain 1991; 114: 1045-1056 .

29.

Johnson KP , Brooks BR , Ford CC , Goodman A , Guarnaccia J , Lisak RP et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years . Mult Scler 2000; 6: 255-266 .